Shareholders demanding a board seat at Alembic, the oldest pharmaceutical firm in the country, to ensure better returns could trigger a similar trend elsewhere, said proxy advisory firms and corporate governance experts.
“We are going to see small shareholders increasingly use this mechanism to voice their concerns,” said Shriram Subramanian, managing director of proxy advisory and corporate governance firm InGovern Research Services.
“Such things happen quite often in the US; this is something new in India,” he added.
Another proxy advisor firm, Institutional Investor Advisory Services
(IIAS), said this case will define the equation between companies
and their shareholders, but more importantly, assess the protection that regulations offer the small investor.
“While small shareholders have attempted to get board seats in the past through this route, this is possibly one of the first cases where a set of sophisticated, discerning shareholders are leveraging this regulation,” it added.
Subramanian, however, said this would require a lot of effort, time and money.
On July 12, Alembic received a notice from Unifi Capital, a portfolio management company, proposing Murali Rajagopalachari’s name as a small shareholders’ director under Section 151 of the Companies
Small shareholders (under the banner of Unifi) are trying to get their nominee appointed to the Alembic board.
However, sources in the investor community said that most of these minority shareholders (around 440 of 1,000) were “created” in the last three days.
The initial plan of a group of small investors was to move a resolution to appoint Rajagopalachari
to the board at the company’s annual general meeting (AGM) on July 28. However, this is now off the list of resolutions to be put to vote at the AGM. The voting would now happen through postal ballot.
prices of both Alembic and Alembic Pharma
rallied in the bourses on Monday. Share
prices of Alembic ended the day’s trade up 7.7 per cent at Rs 43.25 a share, thanks to shareholder activism. Shares were up 11 per cent in the morning session. Alembic Pharma
shares, too, were up marginally.
Alembic de-merged Alembic Pharma
in 2011 with the intention of pursuing growth in formulations and export businesses. The holding company, Alembic, has interests in real estate (it has unused land assets), too. It also has a market capitalisation of Rs 1,190 crore, but holds 30 per cent in Alembic Pharma, which has a market capitalisation of a little over Rs 10,304 crore. Many small shareholders feel the share
is undervalued and there is potential to unlock it.
While Unifi Capital
did not answer e-mails sent to them, they are estimated to have around 3 per cent stake in Alembic. This could not be verified.
A source close to the company, who did not want to be named, presented a different picture: “Unifi is trying to misuse a provision in the Companies
Act, as it wants mirror shareholding in Alembic Pharma
for Alembic shareholders. This would be unfair for Alembic Pharma
The company could, however, take recourse to technical grounds for refusal to appoint such a director, said legal experts.
“It might say the director proposed by the small shareholders does not meet requirements and eligibility criteria of an independent director under law,” said Lalit Kumar, partner, J Sagar Associates.
An IIAS statement said, “the board has discretionary powers — and not absolute, as many argue, and may consider quashing Murali Rajagopalachari’s appointment as a small shareholders’ director. But, these discretionary powers are given to the board to protect the company against frivolous agendas, or incompetence, or both”.
The proxy advisory firm said for the board to use these discretionary powers to turn down a genuine agenda will be a misuse of the regulatory headroom it has been provided.